A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)
Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-...
Saved in:
| Published in: | Scientific reports Vol. 13; no. 1; p. 11327 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
Nature Publishing Group UK
25-07-2023
Nature Publishing Group Nature Portfolio |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission. |
|---|---|
| AbstractList | Abstract Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission. Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission. |
| ArticleNumber | 11327 |
| Author | Harper-Wynne, Catherine Lee, Lennard Y. W. Ying, Yuxin Benny, Liza Ghafoor, Qamar Pascoe, Jennifer S. Mew, Rosie Johnson, Peter Beggs, Andrew Clark, James J. Grumett, Simon Liu, Justin K. H. Swarup, Sanskriti Potter, Vanessa A. Rozmanowski, Stefan Roques, Tom W. Roux, René L. Lomas, Oliver Sintler, Martin Roylance, Rebecca Bytyci, Jola Barnard, Matthew Little, Martin Rigg, Anne S. Williams, Sophie Therese Taylor, Harriet Middleton, Gary Sheehan, Remarez Tuthill, Mark Starkey, Thomas Al-Hajji, Youssra Appanna, Nathan Panneerselvam, Hari Randle, Amelia Middleton, Mark Khan, Sam Kahn, Rachel Protheroe, Andrew Iveson, Tim Eastlake, Leonie Patel, Vijay Tillett, Tania Watts, Isabella Cheng, Vinton Williams, Sarah Lee, Siow Ming Burke, Emma Burnett, Alexander Gerrand, Kate Patel, Grisma Tilby, Michael Cattell, Emma L. Lydon, Anna Shah, Ketan Fittall, Matthew W. Robinson, Tim M. Fowler, Tom Mckenzie, Hayley Ionescu, Maria C. Platt, James R. Tripathy, Arvind R. Lee, Alvin J. X. |
| Author_xml | – sequence: 1 givenname: Thomas surname: Starkey fullname: Starkey, Thomas organization: Institute of Cancer and Genomic Sciences, University of Birmingham – sequence: 2 givenname: Maria C. surname: Ionescu fullname: Ionescu, Maria C. organization: UK Health Security Agency – sequence: 3 givenname: Michael surname: Tilby fullname: Tilby, Michael organization: University Hospitals Birmingham NHS Foundation Trust – sequence: 4 givenname: Martin surname: Little fullname: Little, Martin organization: Oxford University Hospitals NHS Trust – sequence: 5 givenname: Emma surname: Burke fullname: Burke, Emma organization: Oxford University Hospitals NHS Trust – sequence: 6 givenname: Matthew W. surname: Fittall fullname: Fittall, Matthew W. organization: Cancer Institute, University College London – sequence: 7 givenname: Sam surname: Khan fullname: Khan, Sam organization: University of Leicester – sequence: 8 givenname: Justin K. H. surname: Liu fullname: Liu, Justin K. H. organization: University of Leeds – sequence: 9 givenname: James R. surname: Platt fullname: Platt, James R. organization: Leeds Institute of Medical Research at St James’s – sequence: 10 givenname: Rosie surname: Mew fullname: Mew, Rosie organization: Torbay and South Devon NHS Foundation Trust – sequence: 11 givenname: Arvind R. surname: Tripathy fullname: Tripathy, Arvind R. organization: Queen Elizabeth Hospital Birmingham – sequence: 12 givenname: Isabella surname: Watts fullname: Watts, Isabella organization: Royal Free London NHS Foundation Trust – sequence: 13 givenname: Sophie Therese surname: Williams fullname: Williams, Sophie Therese organization: University of Sheffield – sequence: 14 givenname: Nathan surname: Appanna fullname: Appanna, Nathan organization: Oxford Medical School, University of Oxford – sequence: 15 givenname: Youssra surname: Al-Hajji fullname: Al-Hajji, Youssra organization: Birmingham Medical School, University of Birmingham – sequence: 16 givenname: Matthew surname: Barnard fullname: Barnard, Matthew organization: UK Health Security Agency – sequence: 17 givenname: Liza surname: Benny fullname: Benny, Liza organization: UK Health Security Agency – sequence: 18 givenname: Alexander surname: Burnett fullname: Burnett, Alexander organization: Weston Park Cancer Centre – sequence: 19 givenname: Jola surname: Bytyci fullname: Bytyci, Jola organization: Department of Oncology, University of Oxford – sequence: 20 givenname: Emma L. surname: Cattell fullname: Cattell, Emma L. organization: Taunton and Somerset NHS Foundation Trust – sequence: 21 givenname: Vinton surname: Cheng fullname: Cheng, Vinton organization: University of Leeds – sequence: 22 givenname: James J. surname: Clark fullname: Clark, James J. organization: Imperial College London – sequence: 23 givenname: Leonie surname: Eastlake fullname: Eastlake, Leonie organization: Royal Cornwall Hospital Trust – sequence: 24 givenname: Kate surname: Gerrand fullname: Gerrand, Kate organization: UK Health Security Agency – sequence: 25 givenname: Qamar surname: Ghafoor fullname: Ghafoor, Qamar organization: University Hospitals Birmingham NHS Foundation Trust – sequence: 26 givenname: Simon surname: Grumett fullname: Grumett, Simon organization: University Hospitals Birmingham NHS Foundation Trust – sequence: 27 givenname: Catherine surname: Harper-Wynne fullname: Harper-Wynne, Catherine organization: Kent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust – sequence: 28 givenname: Rachel surname: Kahn fullname: Kahn, Rachel organization: Blood Cancer UK – sequence: 29 givenname: Alvin J. X. surname: Lee fullname: Lee, Alvin J. X. organization: University College London – sequence: 30 givenname: Oliver surname: Lomas fullname: Lomas, Oliver organization: Oxford University Hospitals NHS Trust – sequence: 31 givenname: Anna surname: Lydon fullname: Lydon, Anna organization: Torbay and South Devon NHS Foundation Trust – sequence: 32 givenname: Hayley surname: Mckenzie fullname: Mckenzie, Hayley organization: University Hospital Southampton NHS Foundation Trust – sequence: 34 givenname: Hari surname: Panneerselvam fullname: Panneerselvam, Hari organization: Wye Valley NHS Trust – sequence: 35 givenname: Jennifer S. surname: Pascoe fullname: Pascoe, Jennifer S. organization: University Hospitals Birmingham NHS Foundation Trust – sequence: 36 givenname: Grisma surname: Patel fullname: Patel, Grisma organization: University College London – sequence: 37 givenname: Vijay surname: Patel fullname: Patel, Vijay organization: National Health Service – sequence: 38 givenname: Vanessa A. surname: Potter fullname: Potter, Vanessa A. organization: University Hospitals Coventry and Warwickshire NHS Trust – sequence: 39 givenname: Amelia surname: Randle fullname: Randle, Amelia organization: Royal College of Physicians – sequence: 40 givenname: Anne S. surname: Rigg fullname: Rigg, Anne S. organization: Guy’s and St Thomas’ NHS Foundation Trust – sequence: 41 givenname: Tim M. surname: Robinson fullname: Robinson, Tim M. organization: University of Bristol – sequence: 42 givenname: Rebecca surname: Roylance fullname: Roylance, Rebecca organization: University College London Hospitals NHS Foundation Trust – sequence: 43 givenname: Tom W. surname: Roques fullname: Roques, Tom W. organization: Norfolk and Norwich University Hospitals NHS Foundation Trust – sequence: 44 givenname: Stefan surname: Rozmanowski fullname: Rozmanowski, Stefan organization: UK Health Security Agency – sequence: 45 givenname: René L. surname: Roux fullname: Roux, René L. organization: Oxford University Hospitals NHS Trust – sequence: 46 givenname: Ketan surname: Shah fullname: Shah, Ketan organization: Oxford University Hospitals NHS Trust – sequence: 47 givenname: Remarez surname: Sheehan fullname: Sheehan, Remarez organization: Nuffield Department of Surgical Sciences, University of Oxford – sequence: 48 givenname: Martin surname: Sintler fullname: Sintler, Martin organization: Sandwell and West Birmingham Hospitals NHS Trust – sequence: 49 givenname: Sanskriti surname: Swarup fullname: Swarup, Sanskriti organization: Department of Oncology, University of Oxford – sequence: 50 givenname: Harriet surname: Taylor fullname: Taylor, Harriet organization: Oxford Medical School, University of Oxford – sequence: 51 givenname: Tania surname: Tillett fullname: Tillett, Tania organization: Royal United Hospital Bath NHS Trust – sequence: 52 givenname: Mark surname: Tuthill fullname: Tuthill, Mark organization: Oxford University Hospitals NHS Trust – sequence: 53 givenname: Sarah surname: Williams fullname: Williams, Sarah organization: University Hospitals Birmingham NHS Foundation Trust – sequence: 54 givenname: Yuxin surname: Ying fullname: Ying, Yuxin organization: Department of Oncology, University of Oxford – sequence: 55 givenname: Andrew surname: Beggs fullname: Beggs, Andrew organization: Institute of Cancer and Genomic Sciences, University of Birmingham – sequence: 56 givenname: Tim surname: Iveson fullname: Iveson, Tim organization: University Hospital Southampton NHS Foundation Trust – sequence: 57 givenname: Siow Ming surname: Lee fullname: Lee, Siow Ming organization: University College London Hospitals NHS Foundation Trust – sequence: 58 givenname: Gary surname: Middleton fullname: Middleton, Gary organization: Institute of Immunology and Immunotherapy, University of Birmingham – sequence: 59 givenname: Mark surname: Middleton fullname: Middleton, Mark organization: Department of Oncology, University of Oxford – sequence: 60 givenname: Andrew surname: Protheroe fullname: Protheroe, Andrew organization: Churchill Hospital, Oxford University Hospitals NHS Foundation Trust – sequence: 61 givenname: Tom surname: Fowler fullname: Fowler, Tom organization: UK Health Security Agency, William Harvey Research Institute – sequence: 62 givenname: Peter surname: Johnson fullname: Johnson, Peter organization: University of Southampton – sequence: 63 givenname: Lennard Y. W. surname: Lee fullname: Lee, Lennard Y. W. email: lennard.lee@oncology.ox.ac.uk, L.lee.2@bham.ac.uk organization: Institute of Cancer and Genomic Sciences, University of Birmingham, Department of Oncology, University of Oxford |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37491478$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1u1DAQgCNURH_oC3BAlri0h4B_Y_uEqqXAikrlQLlajjPZzSprBztp1RvvwIXn40nw7pbSciAXx_Y339jjOSz2fPBQFC8Ifk0wU28SJ0KrElNWskprXOonxQHFXJSUUbr34H-_OE5phfMnqOZEPyv2meSacKkOip9naAjD1NuxC75MzvaARlgPIdoeOZvg1_cfLvgxhh7Bte2nLYhCi2aXX-fvSqJR0yXIIBqW4MN4OwCyvkERshMaFKbRhTWgmGcJdR4N2QB-TOimG5c5hXcQN-vnftFvAk-uPs1mn0-fF09b2yc4vhuPiqv3519mH8uLyw_z2dlF6QQnY1lRS-rWEkwl1s5VoDFX1EkmGyUqYZVtamsBnKNCsKomBNdK2po2gnPAwI6K-c7bBLsyQ-zWNt6aYDuzXQhxYWwcO9eDqamVjW4llczx1nLdWsoqRQm0kgjeZNfbnWuY6jU0Ll8zl_GR9PGO75ZmEa5NftFKVZRnw8mdIYZvE6TRrLvkoM-VgTAlQxWnXBAlVEZf_YOuwhR9rtWGIhJXTFSZojvKxZBShPb-NARv0iqzaySTG8lsG8noHPTy4T3uQ_60TQbYDkh5yy8g_s39H-1vCkHXhQ |
| CitedBy_id | crossref_primary_10_1038_s41467_024_49285_y crossref_primary_10_1016_S1470_2045_24_00107_4 crossref_primary_10_1016_j_emc_2024_02_002 crossref_primary_10_1111_tid_14194 crossref_primary_10_3389_fonc_2023_1280416 crossref_primary_10_2147_IDR_S431126 |
| Cites_doi | 10.1016/S1470-2045(20)30442-3 10.1016/j.jtho.2021.10.015 10.1038/s43018-021-00275-9 10.1016/S1470-2045(22)00273-X 10.1016/S1470-2045(21)00715-4 10.1001/jamaoncol.2022.5974 10.1001/jamanetworkopen.2023.9694 10.1016/S0140-6736(20)31187-9 10.1038/s41571-020-0370-6 10.1038/s41416-022-01951-y 10.1016/j.ejca.2022.06.038 10.1016/j.ejca.2021.10.014 10.1186/s12879-022-07068-0 10.1016/S0140-6736(20)31173-9 10.3390/v14050961 10.1016/S1470-2045(21)00213-8 10.1016/j.ccell.2021.11.006 10.1200/JCO.21.01891 10.1016/j.annonc.2021.04.019 10.1016/S2352-3026(21)00199-X 10.1016/j.ccell.2020.07.009 10.1186/s12879-022-07781-w 10.1186/s12885-022-09932-3 10.1016/j.ccell.2022.02.012 10.1136/ard-2022-222954 |
| ContentType | Journal Article |
| Contributor | Murphy, Gillian Robinson, Kate Kinloch, Emma Lam, Emily Rhodes, Malcolm |
| Contributor_xml | – sequence: 1 givenname: Emma surname: Kinloch fullname: Kinloch, Emma – sequence: 2 givenname: Emily surname: Lam fullname: Lam, Emily – sequence: 3 givenname: Gillian surname: Murphy fullname: Murphy, Gillian – sequence: 4 givenname: Malcolm surname: Rhodes fullname: Rhodes, Malcolm – sequence: 5 givenname: Kate surname: Robinson fullname: Robinson, Kate |
| Copyright | The Author(s) 2023 2023. The Author(s). The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2023 – notice: 2023. The Author(s). – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| CorporateAuthor | NCRI Consumer Forum |
| CorporateAuthor_xml | – name: NCRI Consumer Forum |
| DBID | C6C CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU COVID DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PIMPY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.1038/s41598-023-36990-9 |
| DatabaseName | SpringerOpen Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central ProQuest Natural Science Collection ProQuest One Community College Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Science Database Biological Science Database Publicly Available Content Database (Proquest) (PQ_SDU_P3) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 11327 |
| ExternalDocumentID | oai_doaj_org_article_b2a7d9f7273c4fa49fa236821ef7154d 10_1038_s41598_023_36990_9 37491478 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | England |
| GeographicLocations_xml | – name: England |
| GrantInformation_xml | – fundername: Cancer Research UK grantid: 30195 – fundername: Department of Health |
| GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ADBBV ADRAZ AENEX AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RIG RNT RNTTT RPM SNYQT UKHRP CGR CUY CVF ECM EIF NPM AAYXX CITATION 7XB 8FK COVID K9. PQEST PQUKI PRINS Q9U 7X8 5PM AFPKN |
| ID | FETCH-LOGICAL-c541t-62a1bfa102709cc6e90482c737d8565a8adbaaeecc25536b110b87ab2d544e0e3 |
| IEDL.DBID | RPM |
| ISSN | 2045-2322 |
| IngestDate | Tue Oct 22 15:09:21 EDT 2024 Tue Sep 17 21:31:17 EDT 2024 Sat Oct 26 06:01:49 EDT 2024 Thu Oct 10 22:53:11 EDT 2024 Fri Nov 22 00:38:26 EST 2024 Sat Nov 02 12:32:17 EDT 2024 Fri Oct 11 20:48:16 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c541t-62a1bfa102709cc6e90482c737d8565a8adbaaeecc25536b110b87ab2d544e0e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368624/ |
| PMID | 37491478 |
| PQID | 2841706356 |
| PQPubID | 2041939 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_b2a7d9f7273c4fa49fa236821ef7154d pubmedcentral_primary_oai_pubmedcentral_nih_gov_10368624 proquest_miscellaneous_2842451858 proquest_journals_2841706356 crossref_primary_10_1038_s41598_023_36990_9 pubmed_primary_37491478 springer_journals_10_1038_s41598_023_36990_9 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-07-25 |
| PublicationDateYYYYMMDD | 2023-07-25 |
| PublicationDate_xml | – month: 07 year: 2023 text: 2023-07-25 day: 25 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2023 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | Naranbhai (CR4) 2022; 40 Ng (CR20) 2022; 14 Mitchell (CR29) 2022; 22 CR19 CR15 CR14 Lee, Quinn, Pradhan, Fedorov, Levitz, Fromowitz, Thakkar, Shapiro, Kabarriti, Ruiz, Andrews (CR17) 2022; 40 CR33 CR10 CR32 CR31 Al Hajji, Taylor, Starkey, Lee, Tilby (CR30) 2022; 127 Lee (CR13) 2020; 21 Barrière (CR8) 2021; 32 Lee (CR12) 2020; 395 Spicer, Chamberlain, Papa (CR28) 2020; 17 Lee (CR24) 2020; 395 Vegivinti (CR21) 2022; 22 Leiner (CR18) 2022; 22 Shapiro (CR9) 2021; 40 CR23 Kuderer (CR25) 2020; 395 Ligumsky (CR3) 2021; 23 Fendler (CR5) 2021 Becerril-Gaitan (CR1) 2022; 160 Pinato (CR16) 2022; 23 Lee (CR26) 2022; 175 Lim (CR7) 2021; 8 Monin (CR6) 2021; 22 Lee (CR27) 2023; 9 Gounant (CR2) 2022; 17 Ambrose (CR22) 2023; 6 Lee (CR11) 2020; 38 M Lee (36990_CR17) 2022; 40 LYW Lee (36990_CR13) 2020; 21 36990_CR31 NM Kuderer (36990_CR25) 2020; 395 Y Al Hajji (36990_CR30) 2022; 127 J Spicer (36990_CR28) 2020; 17 J Barrière (36990_CR8) 2021; 32 H Mitchell (36990_CR29) 2022; 22 A Fendler (36990_CR5) 2021 36990_CR23 LYW Lee (36990_CR27) 2023; 9 V Gounant (36990_CR2) 2022; 17 SH Lim (36990_CR7) 2021; 8 LYW Lee (36990_CR12) 2020; 395 A Becerril-Gaitan (36990_CR1) 2022; 160 TI Ng (36990_CR20) 2022; 14 CTR Vegivinti (36990_CR21) 2022; 22 LYW Lee (36990_CR11) 2020; 38 H Ligumsky (36990_CR3) 2021; 23 LC Shapiro (36990_CR9) 2021; 40 DJ Pinato (36990_CR16) 2022; 23 J Leiner (36990_CR18) 2022; 22 36990_CR19 L Monin (36990_CR6) 2021; 22 LYW Lee (36990_CR26) 2022; 175 V Naranbhai (36990_CR4) 2022; 40 36990_CR10 36990_CR32 LY Lee (36990_CR24) 2020; 395 36990_CR33 N Ambrose (36990_CR22) 2023; 6 36990_CR14 36990_CR15 |
| References_xml | – volume: 21 start-page: 1309 year: 2020 end-page: 1316 ident: CR13 article-title: COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: A prospective cohort study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(20)30442-3 contributor: fullname: Lee – volume: 17 start-page: 239 year: 2022 end-page: 251 ident: CR2 article-title: Efficacy of severe acute respiratory syndrome coronavirus-2 vaccine in patients with thoracic Cancer: A prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2021.10.015 contributor: fullname: Gounant – year: 2021 ident: CR5 article-title: Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: The CAPTURE study publication-title: Nat. Cancer doi: 10.1038/s43018-021-00275-9 contributor: fullname: Fendler – volume: 23 start-page: 865 issue: 7 year: 2022 end-page: 875 ident: CR16 article-title: Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: Results from the retrospective, multicentre, OnCovid registry study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(22)00273-X contributor: fullname: Pinato – ident: CR14 – volume: 23 start-page: 193 issue: 2 year: 2021 end-page: 195 ident: CR3 article-title: Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(21)00715-4 contributor: fullname: Ligumsky – volume: 9 start-page: 188 year: 2023 end-page: 196 ident: CR27 article-title: Association of SARS-CoV-2 spike protein antibody vaccine response with infection severity in patients with cancer: A national COVID cancer cross-sectional evaluation publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2022.5974 contributor: fullname: Lee – ident: CR10 – volume: 6 start-page: e239694 year: 2023 ident: CR22 article-title: Neutralizing monoclonal antibody use and COVID-19 infection outcomes publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2023.9694 contributor: fullname: Ambrose – ident: CR33 – volume: 395 start-page: 1907 year: 2020 end-page: 1918 ident: CR25 article-title: Clinical impact of COVID-19 on patients with cancer (CCC19): A cohort study publication-title: Lancet Lond. Engl. doi: 10.1016/S0140-6736(20)31187-9 contributor: fullname: Kuderer – volume: 17 start-page: 329 year: 2020 end-page: 331 ident: CR28 article-title: Provision of cancer care during the COVID-19 pandemic publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-020-0370-6 contributor: fullname: Papa – volume: 127 start-page: 1827 year: 2022 end-page: 1836 ident: CR30 article-title: Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: A systematic review publication-title: Br. J. Cancer doi: 10.1038/s41416-022-01951-y contributor: fullname: Tilby – volume: 175 start-page: 1 year: 2022 end-page: 10 ident: CR26 article-title: COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2022.06.038 contributor: fullname: Lee – ident: CR23 – volume: 160 start-page: 243 year: 2022 end-page: 260 ident: CR1 article-title: Immunogenicity and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after coronavirus disease 2019 (COVID-19) vaccination in patients with cancer: A systematic review and meta-analysis publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2021.10.014 contributor: fullname: Becerril-Gaitan – volume: 22 start-page: 107 year: 2022 ident: CR21 article-title: Efficacy of antiviral therapies for COVID-19: A systematic review of randomized controlled trials publication-title: BMC Infect. Dis. doi: 10.1186/s12879-022-07068-0 contributor: fullname: Vegivinti – volume: 395 start-page: 1919 year: 2020 end-page: 1926 ident: CR24 article-title: COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study publication-title: Lancet Lond. Engl. doi: 10.1016/S0140-6736(20)31173-9 contributor: fullname: Lee – ident: CR19 – volume: 14 start-page: 961 year: 2022 ident: CR20 article-title: Antiviral drug discovery for the treatment of COVID-19 infections publication-title: Viruses doi: 10.3390/v14050961 contributor: fullname: Ng – volume: 22 start-page: 765 year: 2021 end-page: 778 ident: CR6 article-title: Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: Interim analysis of a prospective observational study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(21)00213-8 contributor: fullname: Monin – volume: 40 start-page: 3 issue: 1 year: 2021 end-page: 5 ident: CR9 article-title: Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer publication-title: Cancer Cell doi: 10.1016/j.ccell.2021.11.006 contributor: fullname: Shapiro – ident: CR15 – ident: CR31 – volume: 40 start-page: 12 year: 2022 end-page: 23 ident: CR4 article-title: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer: The CANVAX cohort study publication-title: J. Clin. Oncol. doi: 10.1200/JCO.21.01891 contributor: fullname: Naranbhai – volume: 32 start-page: 1053 year: 2021 end-page: 1055 ident: CR8 article-title: Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1016/j.annonc.2021.04.019 contributor: fullname: Barrière – volume: 8 start-page: e542 year: 2021 end-page: e544 ident: CR7 article-title: Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma publication-title: Lancet Haematol. doi: 10.1016/S2352-3026(21)00199-X contributor: fullname: Lim – ident: CR32 – volume: 38 start-page: 306 year: 2020 end-page: 307 ident: CR11 article-title: Utility of COVID-19 screening in cancer patients publication-title: Cancer Cell doi: 10.1016/j.ccell.2020.07.009 contributor: fullname: Lee – volume: 22 start-page: 802 year: 2022 ident: CR18 article-title: Characteristics and outcomes of COVID-19 patients during B.1.1.529 (Omicron) dominance compared to B.1.617.2 (Delta) in 89 German hospitals publication-title: BMC Infect. Dis. doi: 10.1186/s12879-022-07781-w contributor: fullname: Leiner – volume: 22 start-page: 850 year: 2022 ident: CR29 article-title: Impact of the COVID-19 pandemic on emergency hospital cancer admissions in a UK region publication-title: BMC Cancer doi: 10.1186/s12885-022-09932-3 contributor: fullname: Mitchell – volume: 40 start-page: 343 year: 2022 end-page: 345 ident: CR17 article-title: Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave publication-title: Cancer Cell doi: 10.1016/j.ccell.2022.02.012 contributor: fullname: Andrews – volume: 395 start-page: 1919 issue: 10241 year: 2020 end-page: 1926 ident: CR12 article-title: COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study publication-title: The Lancet doi: 10.1016/S0140-6736(20)31173-9 contributor: fullname: Lee – volume: 14 start-page: 961 year: 2022 ident: 36990_CR20 publication-title: Viruses doi: 10.3390/v14050961 contributor: fullname: TI Ng – ident: 36990_CR19 doi: 10.1136/ard-2022-222954 – volume: 160 start-page: 243 year: 2022 ident: 36990_CR1 publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2021.10.014 contributor: fullname: A Becerril-Gaitan – volume: 32 start-page: 1053 year: 2021 ident: 36990_CR8 publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. doi: 10.1016/j.annonc.2021.04.019 contributor: fullname: J Barrière – volume: 22 start-page: 802 year: 2022 ident: 36990_CR18 publication-title: BMC Infect. Dis. doi: 10.1186/s12879-022-07781-w contributor: fullname: J Leiner – volume: 9 start-page: 188 year: 2023 ident: 36990_CR27 publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2022.5974 contributor: fullname: LYW Lee – volume: 395 start-page: 1919 issue: 10241 year: 2020 ident: 36990_CR12 publication-title: The Lancet doi: 10.1016/S0140-6736(20)31173-9 contributor: fullname: LYW Lee – volume: 23 start-page: 193 issue: 2 year: 2021 ident: 36990_CR3 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(21)00715-4 contributor: fullname: H Ligumsky – volume: 22 start-page: 765 year: 2021 ident: 36990_CR6 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(21)00213-8 contributor: fullname: L Monin – volume: 40 start-page: 12 year: 2022 ident: 36990_CR4 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.21.01891 contributor: fullname: V Naranbhai – volume: 175 start-page: 1 year: 2022 ident: 36990_CR26 publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2022.06.038 contributor: fullname: LYW Lee – ident: 36990_CR15 – volume: 22 start-page: 850 year: 2022 ident: 36990_CR29 publication-title: BMC Cancer doi: 10.1186/s12885-022-09932-3 contributor: fullname: H Mitchell – ident: 36990_CR32 – volume: 38 start-page: 306 year: 2020 ident: 36990_CR11 publication-title: Cancer Cell doi: 10.1016/j.ccell.2020.07.009 contributor: fullname: LYW Lee – volume: 6 start-page: e239694 year: 2023 ident: 36990_CR22 publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2023.9694 contributor: fullname: N Ambrose – volume: 17 start-page: 239 year: 2022 ident: 36990_CR2 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2021.10.015 contributor: fullname: V Gounant – volume: 22 start-page: 107 year: 2022 ident: 36990_CR21 publication-title: BMC Infect. Dis. doi: 10.1186/s12879-022-07068-0 contributor: fullname: CTR Vegivinti – ident: 36990_CR31 – year: 2021 ident: 36990_CR5 publication-title: Nat. Cancer doi: 10.1038/s43018-021-00275-9 contributor: fullname: A Fendler – volume: 40 start-page: 343 year: 2022 ident: 36990_CR17 publication-title: Cancer Cell doi: 10.1016/j.ccell.2022.02.012 contributor: fullname: M Lee – volume: 40 start-page: 3 issue: 1 year: 2021 ident: 36990_CR9 publication-title: Cancer Cell doi: 10.1016/j.ccell.2021.11.006 contributor: fullname: LC Shapiro – ident: 36990_CR23 – volume: 21 start-page: 1309 year: 2020 ident: 36990_CR13 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(20)30442-3 contributor: fullname: LYW Lee – volume: 8 start-page: e542 year: 2021 ident: 36990_CR7 publication-title: Lancet Haematol. doi: 10.1016/S2352-3026(21)00199-X contributor: fullname: SH Lim – volume: 23 start-page: 865 issue: 7 year: 2022 ident: 36990_CR16 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(22)00273-X contributor: fullname: DJ Pinato – volume: 127 start-page: 1827 year: 2022 ident: 36990_CR30 publication-title: Br. J. Cancer doi: 10.1038/s41416-022-01951-y contributor: fullname: Y Al Hajji – volume: 395 start-page: 1919 year: 2020 ident: 36990_CR24 publication-title: Lancet Lond. Engl. doi: 10.1016/S0140-6736(20)31173-9 contributor: fullname: LY Lee – volume: 395 start-page: 1907 year: 2020 ident: 36990_CR25 publication-title: Lancet Lond. Engl. doi: 10.1016/S0140-6736(20)31187-9 contributor: fullname: NM Kuderer – volume: 17 start-page: 329 year: 2020 ident: 36990_CR28 publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-020-0370-6 contributor: fullname: J Spicer – ident: 36990_CR33 – ident: 36990_CR14 – ident: 36990_CR10 |
| SSID | ssj0000529419 |
| Score | 2.481152 |
| Snippet | Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.... Abstract Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)... |
| SourceID | doaj pubmedcentral proquest crossref pubmed springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 11327 |
| SubjectTerms | 631/67 692/308/409 Cancer Case-Control Studies Coronaviruses COVID-19 COVID-19 - epidemiology England - epidemiology Genotype & phenotype Hospitalization Humanities and Social Sciences Humans Mortality multidisciplinary Neoplasms - epidemiology Phenotype Phenotypes SARS-CoV-2 Science Science (multidisciplinary) Severe acute respiratory syndrome coronavirus 2 |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LaxUxFA5aENyIb8dWieBC0dDJY_JY1tuWiqCCVtyFvAYLMlM69y668z-48ff5SzzJzJ16feDGbRKYTM53cs5JTr6D0GPPIKyikRPWipoI4SjxIUqSpAwicBZVyOcdR-_U6496_yDT5MylvnJO2EgPPC7crmdORdNmMxtE64RpHeNSM5paBeY_lt23lj8FUyOrNzOCmumVTM317gCWKr8mY5xwCVswMRuWqBD2_8nL_D1Z8pcb02KIDq-ja5MHiffGmd9Al1J3E10Za0qe30Lf9vDpXJSLDCCChCf-qc84gM36_uXrlJ-OL6i-cd_ixZsPL_cJNXi6tME5_avPZ7TYdRGXVy8p4n61BJQmnDkmBnzS4YmadcD5TBc-ATA6y-1TfRD85PjVYvH26W10fHjwfnFEpvILJDSCLolkjvrWgQeiahOCTAa0nQXFVdTgBjrtoncuAQYgLOHSgyPhtXKexUaIVCd-B211fZfuISyFp40CM2jaKCDG0t6LlEBAHsKfGGiFnq1FYU9Hlg1bbse5tqPgLAjOFsFZU6EXWVrzyMyQXRoAN3bCjf0Xbiq0s5a1ndR2sGCrM50Qb2SFHs3doHD5FsV1qV-VMUw04OboCt0doTHPhCthqFDQozdAszHVzZ7u5FMh9YZ_LY91KvR8ja-Lef19Le7_j7XYRldZVow6k3bsoK3l2So9QJeHuHpY1OoH3KEm0A priority: 102 providerName: Directory of Open Access Journals |
| Title | A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP) |
| URI | https://link.springer.com/article/10.1038/s41598-023-36990-9 https://www.ncbi.nlm.nih.gov/pubmed/37491478 https://www.proquest.com/docview/2841706356 https://search.proquest.com/docview/2842451858 https://pubmed.ncbi.nlm.nih.gov/PMC10368624 https://doaj.org/article/b2a7d9f7273c4fa49fa236821ef7154d |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbYSkhcEG9CS2UkDiBwN37k4WNJWxUhoBIUcYv8CqzUJqvN7qE3_gMXfh-_hLHjbLs8LlyTSLEy32S-sWe-QeipZpBWUcsJa0RKhFCUaGNz4vLcCMOZLYzf7zj-ULz7XB4cepmcfOyFCUX7Rs_22rPzvXb2NdRWzs_NdKwTm568rSj8dn1jw3SCJkAOr-Tog6I3k4LK2CGT8nLaQ5TynWSME57D75d4rVBeCEmFH692JSAF3f6_kc0_ayZ_OzgN8ejoFroZiSTeHxZ8G11z7R10fRgteXEX_djH8_VsLtKDJRyOMlRn2EDo-vnteyxTx5eK37hrcPX-0-sDQiWOZzfYV4F1fqsWq9bi0PziLO5WSwCrw15qosezFkeF1h77rV14BaBp4a_HMSH42embqjp5fg-dHh1-rI5JnMJATCbokuRMUd0oICJFKo3JnQSnZ6bghS2BDapSWa2UAyhAdsJzDXxCl4XSzGZCuNTx-2ir7Vr3EOFcaJoVEA1lYwWkWqXWwjmwlYYsyBqaoBejKer5ILZRh0NyXtaDDWuwYR1sWMsEvfLWWj_phbLDhW7xpY5wqTVThZWNZ2lGNErIRjEAD6OuKYA92gTtjLauo_f2NYRsryrEszxBT9a3we_8YYpqXbcKzzCRAdspE_RggMZ6JSO0ElRugGZjqZt3AOpB23uEdoJejvi6XNe_v8Wj_3_TNrrBvGekXrFjB20tFyv3GE16u9oNGxS7wbt-AfpuKII |
| link.rule.ids | 230,315,729,782,786,866,887,2106,27933,27934,53800,53802 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZoEYIL70eggJE4gMDd-LF5HEvaaqs-qESLerP8SrtSm6w2uwdu_Acu_D5-CWMn2XZ5XHqNI9nJfOOZsWe-QeitZhBWUcsJK0VMhFCUaGMT4pLECMOZTY0_7xh9SQ9Oss0tT5OT9LUwIWnf6PF6dX6xXo3PQm7l5MIM-jyxweF-QWHb9YUNgxV0ExQ2jq9E6S2nN8sFzbsamZhngwbslK8lY5zwBDZg4tlCeSpyKnyDtSsmKTD3_8vd_Dtr8o-r02CRtu9d91vuo7udD4o32vEH6IarHqJbbVfKb4_Qzw08WbT1Ig0I0eGOweocG7B6v77_6DLc8SVZOK5LXHz-urNJaI67ax_sE8hqf8qLVWVxqJtxFtfzGeDcYc9S0eBxhTty1wb7U2GYAoA49c-7DiP43fFuURy-f4yOt7eOihHpGjgQMxR0RhKmqC4V-DBpnBuTuBz2C2ZSntoMHEmVKauVcoAiCGx4osEV0VmqNLNDIVzs-BO0WtWVe4ZwIjQdpmBI89IKiNIyrYVzIGQNAZQ1NEIfehnKScvTIcP9Os9kK3wJwpdB-DKP0Ccv5sWbnmM7PKinp7KTjtRMpTYvvYNnRKlEXioGsmLUlSk4njZCaz1IZKf4jQRr7wmJ-DCJ0JvFMKisv4dRlavn4R0mhuAoZRF62mJqsZIekxHKltC2tNTlEUBWoAXvkRShjz0wL9f1_3_x_PozvUa3R0f7e3Jv52D3BbrDvHrFnvhjDa3OpnP3Eq00dv4qKOdv-W09RA |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZoEYgL70eggJE4gMBN_Ng8uJXdrloVykrQipvlV2ClNlltdg_c-A9c-H38EsZOsu3yuMDVtmQn89kzY898g9BTzcCtopYTVoqECKEo0camxKWpEYYzmxl_37H3Pjv8mI92PU3Oqz4XJgTtGz3drk5Ot6vp5xBbOTs1cR8nFk_eDikcuz6xIZ7ZMt5AF2HTJuycp97yerNC0KLLk0l4Hjegq3w-GeOEp3AIE88YyjNRUOGLrJ1TS4G9_08m5--Rk788nwatNL72P99zHV3tbFG80465gS646ia61Fan_HILfd_Bs1V5L9KAMB3umKxOsAHt9-Prty7SHZ-RhuO6xMN3x_sjQgvcPf9gH0hW-9terCqLQ_6Ms7heLgDvDnu2igZPK9yRvDbY3w7DFADIuW_vKo3gZ0cHw-Hk-W10NN79MNwjXSEHYgaCLkjKFNWlAlsmSwpjUlfAucFMxjObg0GpcmW1Ug7QBA4OTzWYJDrPlGZ2IIRLHL-DNqu6cvcQToWmgwwUalFaAd5arrVwDgStwZGyhkboRS9HOWv5OmR4Z-e5bAEgAQAyAEAWEXrtRb0a6bm2Q0M9_yQ7CUnNVGaL0ht6RpRKFKViIC9GXZmBAWojtNUDRXYHQCNB63tiIj5II_Rk1Q1b17_HqMrVyzCGiQEYTHmE7ra4Wq2kx2WE8jXErS11vQfQFejBezRF6GUPzrN1_f1f3P_3mR6jy5PRWL7ZPzx4gK4wv8MSz_-xhTYX86V7iDYau3wU9udP5EA_xA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+population-scale+temporal+case%E2%80%93control+evaluation+of+COVID-19+disease+phenotype+and+related+outcome+rates+in+patients+with+cancer+in+England+%28UKCCP%29&rft.jtitle=Scientific+reports&rft.au=Starkey%2C+Thomas&rft.au=Ionescu%2C+Maria+C.&rft.au=Tilby%2C+Michael&rft.au=Little%2C+Martin&rft.date=2023-07-25&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2045-2322&rft.volume=13&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-023-36990-9&rft.externalDocID=10_1038_s41598_023_36990_9 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |